BioLineRx Ltd. (BLRX)
Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 202619 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to BioLineRx Ltd.’s names, not what it holds today.
46 published
7 published
| Granted | Patent | Title | Field | Owner as printed |
|---|---|---|---|---|
| May 6, 2025 | 12,291,570 | Treatment of metastatic pancreatic adenocarcinoma | Pharmaceuticals | BioLineRx Ltd. |
| Apr 8, 2025 | 12,268,725 | Composition of BL-8040 | Pharmaceuticals | BioLineRx Ltd. |
| Mar 25, 2025 | 12,257,285 | Composition of BL-8040 | Pharmaceuticals | BioLineRx Ltd. |
| May 28, 2024 | 11,993,631 | Process for manufacturing peptide | Biotechnology | BioLineRx Ltd. |
| May 16, 2023 | 11,648,293 | Compositions and methods for treating cancer | Pharmaceuticals | BioLineRx Ltd. |
| May 9, 2023 | 11,642,393 | Compositions and methods for treating cancer | Pharmaceuticals | BioLineRx Ltd. |
| May 2, 2023 | 11,638,743 | Compositions and methods for treating cancer | Pharmaceuticals | BioLineRx Ltd. |
| May 2, 2023 | 11,638,742 | Compositions and methods for treating cancer | Pharmaceuticals | BioLineRx Ltd. |
| Mar 28, 2023 | 11,612,638 | Compositions and methods for treating cancer | Pharmaceuticals | BioLineRx Ltd. |
| Mar 21, 2023 | 11,607,444 | Compositions and methods for treating cancer | Pharmaceuticals | BioLineRx Ltd. |
| Published | Application | Title | Field | Owner as printed |
|---|---|---|---|---|
| Jun 19, 2025 | 2025/0195607 | COMPOSITION OF BL-8040 | Pharmaceuticals | BioLineRx Ltd. |
| May 29, 2025 | 2025/0170208 | COMPOSITION OF BL-8040 | Pharmaceuticals | BioLineRx Ltd. |
| May 29, 2025 | 2025/0170207 | COMPOSITION OF BL-8040 | Pharmaceuticals | BioLineRx Ltd. |
| May 29, 2025 | 2025/0170206 | COMPOSITION OF BL-8040 | Pharmaceuticals | BioLineRx Ltd. |
| May 29, 2025 | 2025/0170205 | COMPOSITION OF BL-8040 | Pharmaceuticals | BioLineRx Ltd. |
| Apr 25, 2024 | 2024/0131111 | COMPOSITION OF BL-8040 | Pharmaceuticals | BioLineRx Ltd. · patent 12,257,285 granted from it |
| Mar 21, 2024 | 2024/0092827 | PROCESS FOR MANUFACTURING PEPTIDE | Biotechnology | BioLineRx Ltd. · patent 11,993,631 granted from it |
| Mar 14, 2024 | 2024/0082348 | COMPOSITION OF BL-8040 | Pharmaceuticals | BioLineRx Ltd. · patent 12,268,725 granted from it |
| Aug 3, 2023 | 2023/0242644 | TREATMENT OF METASTATIC PANCREATIC ADENOCARCINOMA | Pharmaceuticals | BioLineRx Ltd. |
| Apr 6, 2023 | 2023/0104343 | CXCR4 INHIBITOR FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND VIRAL INFECTIONS | Pharmaceuticals | BioLineRx Ltd. |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.